Cocrystal Pharma Inc COCP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.95
- Day Range
- $0.95–0.98
- 52-Week Range
- $0.86–2.67
- Bid/Ask
- $0.95 / $1.01
- Shares Outstanding
- 13.79M
- Market Cap
- $13.10M
- Volume/Avg
- 12,078 / 106,428
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 51.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.cocrystalpharma.com
Valuation
|
Metric
|
COCP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.18 |
Price/Sales | 51.48 |
Price/Cash Flow | — |
Price/Earnings
COCP
Financial Strength
|
Metric
|
COCP
|
|---|---|
Quick Ratio | 2.44 |
Current Ratio | 2.66 |
Interest Coverage | — |
Quick Ratio
COCP
Profitability
|
Metric
|
COCP
|
|---|---|
Return on Assets (Normalized) | −91.52% |
Return on Equity (Normalized) | −139.12% |
Return on Invested Capital (Normalized) | −112.22% |
Return on Assets
COCP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<F$&%M | LOCK|>!&j | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Pr<$Fxw | LOCK|#$@Tm | $71B | |||
| argenx SE ADR
ARGX
| LOCK|pGK^$@ | LOCK|xk% | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|tt^f<>! | LOCK|H> | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|VyFrQl | LOCK|Z%v? | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|v^#t!sK | LOCK|^Yby | $26B | |||
| Moderna Inc
MRNA
| LOCK|hP>##BS | LOCK|z@ | $25B | |||
| Incyte Corp
INCY
| LOCK|b>$b%? | LOCK|m# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#Hz<>R | LOCK|&> | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<WW!Swh | LOCK|HZN | $16B |
United States